Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why.

Intellia Therapeutics, a CRISPR gene-editing biotech company, has surged 70% this year and Wall Street expects another 70% gain over the next 12 months. The company is preparing FDA submission for lonvo-z, a one-time treatment for hereditary angioedema that showed 87% reduction in attacks in phase 3 trials. With positive clinical data and a second late-stage candidate in development, Intellia is transitioning toward commercial-stage operations.